AllianceBernstein’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-331,999
| Closed | -$7.2M | – | 3171 |
|
|
2017
Q2 | $7.2M | Buy |
331,999
+307,849
| +1,275% | +$5.59M | 0.01% | 1038 |
|
|
2017
Q1 | $339K | Sell |
24,150
-4,800
| -17% | -$78.6K | ﹤0.01% | 2666 |
|
|
2016
Q4 | $543K | Hold |
28,950
| – | – | ﹤0.01% | 2542 |
|
|
2016
Q3 | $478K | Hold |
28,950
| – | – | ﹤0.01% | 2547 |
|
|
2016
Q2 | $389K | Sell |
28,950
-800
| -3% | -$11.7K | ﹤0.01% | 2602 |
|
|
2016
Q1 | $455K | Hold |
29,750
| – | – | ﹤0.01% | 2445 |
|
|
2015
Q4 | $591K | Sell |
29,750
-3,500
| -11% | -$66.5K | ﹤0.01% | 2388 |
|
|
2015
Q3 | $579K | Sell |
33,250
-100
| -0.3% | -$2.04K | ﹤0.01% | 2433 |
|
|
2015
Q2 | $674K | Buy |
33,350
+4,100
| +14% | +$79.1K | ﹤0.01% | 2473 |
|
|
2015
Q1 | $515K | Hold |
29,250
| – | – | ﹤0.01% | 2479 |
|
|
2014
Q4 | $476K | Buy |
29,250
+1,950
| +7% | +$35.8K | ﹤0.01% | 2533 |
|
|
2014
Q3 | $603K | Buy |
27,300
+14,100
| +107% | +$289K | ﹤0.01% | 2448 |
|
|
2014
Q2 | $266K | Buy |
13,200
+13,110
| +14,567% | +$222K | ﹤0.01% | 2715 |
|
|
2014
Q1 | $2K | Sell |
90
-3,929
| -98% | -$54.1K | ﹤0.01% | 3491 |
|
|
2013
Q4 | $41K | Sell |
4,019
-7,293
| -64% | -$88.1K | ﹤0.01% | 3015 |
|
|
2013
Q3 | $146K | Sell |
11,312
-1,673
| -13% | -$20.6K | ﹤0.01% | 2921 |
|
|
2013
Q2 | $154K | Buy |
+12,985
| New | +$141K | ﹤0.01% | 2895 |
|
Other funds holding AMRI
AllianceBernstein's AMRI Position: Q3 2017 in Review
AllianceBernstein sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 331,999 shares — an estimated $7.2M sold.
AllianceBernstein first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $7.2M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- AllianceBernstein reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- AllianceBernstein sold 331,999 Albany Molecular Research Inc shares in Q3 2017, an estimated $7.2M.
- AllianceBernstein first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- AllianceBernstein's Albany Molecular Research Inc position peaked at $7.2M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on AllianceBernstein's 13F filing for Q3 2017, filed 13 Nov 2017.